Open access research partnership to 'crowdsource' new myeloma drugs | Pharmafile

Abstract

The aim is to make the products of the research collaboration – potential new drug targets – available to other researchers, patent-free and open access. The SGC is a public-private partnership that supports the discovery of new medicines through open access research. In this first partnership of its kind in Europe, Myeloma UK and the SGC have explicitly agreed not to file for patents on any of the collaborative research, and to make all reagents and knowledge available without restriction to the wider research community. This includes pharmaceutical, biotech, and academic research groups. The SGC and Myeloma UK will make any research tools developed freely available to the research community immediately and without restriction. Since no patent protection will be taken on any of the results of this collaboration, any investigator in the world will have complete freedom to use the data to advance science and the discovery of new medicines.